 VANCOUVER, Washington, June 22, 2022 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY CytoDyn or the Company, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research Development, will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022. 